Serial Number | 97180459 |
Word Mark | MOLECURE |
Filing Date | Monday, December 20, 2021 |
Status | 807 - SU - NON-FINAL ACTION - MAILED |
Status Date | Wednesday, January 24, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
Published for Opposition Date | Tuesday, May 23, 2023 |
Description of Mark | The mark consists of the word "MOLECURE" in stylized font. |
Goods and Services | Pharmaceutical, medical and veterinary preparations and substances, namely, pharmaceutical preparations and substances for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemico-pharmaceutical preparations for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; biochemical preparations for medical use, namely, biochemical preparations for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer |
Pseudo Mark | MOLE CURE |
Indication of Colors claimed | Color is not claimed as a feature of the mark. |
Goods and Services | Medical and pharmacological research services; research and development services in the field of antibodies; research and development services in the field of immunology; research and development in the pharmaceutical and biotechnology fields; drug discovery services; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; biological research, clinical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer, and medical research; medical laboratory services; scientific laboratory services; analysis of human tissues for medical research; laboratory services, namely, laboratory research services, medical laboratory services, scientific laboratory services relating to the production of monoclonal antibodies; medical research and scientific analysis in the field of immunology and antibodies; scientific research for medical purposes in the area of cancerous diseases; biomedical research services; biological research; research relating to biotechnology; clinical research and medical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemical research and analysis services including analytical services relating to medicines, pharmaceutical preparations and biochemistry; research laboratories, namely, laboratory research in the field of chemistry; scientific and biotechnology research in the field of gene therapy; DNA screening for scientific research purposes; biological research, namely, cell separation research services; research and development services in the field of immunohistology; scientific research in the field of genetics and genetic engineering; consultancy relating to research and development in the field of therapeutics; product custom design and development of medical technology; services for the development of methods of testing, namely, development and establishment of testing specifications and procedures in the field of biotechnology and pharmaceutical fields; conducting technical project studies, namely, technical research in the field of pharmaceutical studies; preparation of project analysis studies, namely, conducting scientific study in the fields of medicine and biotechnology; technical consultancy relating to product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory services relating to scientific research; providing information about the results of clinical trials for others for pharmaceutical products |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Monday, December 27, 2021 |
Primary Code | 005 |
First Use Anywhere Date | Thursday, November 30, 2017 |
First Use In Commerce Date | Monday, November 30, 2020 |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Thursday, April 20, 2023 |
Primary Code | 042 |
First Use Anywhere Date | Thursday, November 30, 2017 |
First Use In Commerce Date | Monday, November 30, 2020 |
Party Name | MOLECURE SPÓLKA AKCYJNA |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | WARSZAWA POLAND 02-089 PL |
Party Name | MOLECURE SPÓLKA AKCYJNA |
Party Type | 11 - New Owner Before Publication |
Legal Entity Type | 03 - Corporation |
Address | WARSZAWA POLAND 02-089 PL |
Party Name | OncoArendi Therapeutics S.A. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 99 - Other |
Address | Warszawa 02-089 PL |
Event Date | Event Description |
Wednesday, January 24, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Wednesday, January 24, 2024 | NON-FINAL ACTION E-MAILED |
Wednesday, January 24, 2024 | SU - NON-FINAL ACTION - WRITTEN |
Wednesday, January 24, 2024 | STATEMENT OF USE PROCESSING COMPLETE |
Thursday, January 4, 2024 | USE AMENDMENT FILED |
Tuesday, January 23, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Thursday, January 4, 2024 | TEAS STATEMENT OF USE RECEIVED |
Tuesday, July 18, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Tuesday, May 23, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, May 23, 2023 | PUBLISHED FOR OPPOSITION |
Wednesday, May 3, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Thursday, April 20, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Thursday, April 20, 2023 | EXAMINER'S AMENDMENT ENTERED |
Thursday, April 20, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Thursday, April 20, 2023 | EXAMINERS AMENDMENT E-MAILED |
Thursday, April 20, 2023 | EXAMINERS AMENDMENT -WRITTEN |
Tuesday, March 28, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Monday, March 27, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Monday, March 27, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Friday, October 14, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Friday, October 14, 2022 | NON-FINAL ACTION E-MAILED |
Friday, October 14, 2022 | NON-FINAL ACTION WRITTEN |
Sunday, September 25, 2022 | ASSIGNED TO EXAMINER |
Wednesday, September 7, 2022 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Monday, December 27, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Thursday, December 23, 2021 | NEW APPLICATION ENTERED |